Top 5 Stocks to Buy Now
→ Your book attached (From Profits Run) (Ad)tc pixel Free HEMO Stock Alerts

Hemogenyx Pharmaceuticals (HEMO) Competitors

Hemogenyx Pharmaceuticals logo
GBX 761 +22.00 (+2.98%)
As of 12:03 PM Eastern
Compare

HEMO vs. SCLP, BTG, ARIX, CIR, and TILS

Should you buy Hemogenyx Pharmaceuticals stock or one of its competitors? MarketBeat compares Hemogenyx Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Hemogenyx Pharmaceuticals include Scancell (SCLP), BTG (BTG), Arix Bioscience (ARIX), Circassia Group (CIR), and Tiziana Life Sciences (TILS). These companies are all part of the "biotechnology" industry.

How does Hemogenyx Pharmaceuticals compare to Scancell?

Scancell (LON:SCLP) and Hemogenyx Pharmaceuticals (LON:HEMO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and media sentiment.

In the previous week, Scancell had 1 more articles in the media than Hemogenyx Pharmaceuticals. MarketBeat recorded 1 mentions for Scancell and 0 mentions for Hemogenyx Pharmaceuticals. Scancell's average media sentiment score of 0.00 equaled Hemogenyx Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Scancell Neutral
Hemogenyx Pharmaceuticals Neutral

1.5% of Scancell shares are owned by institutional investors. Comparatively, 0.2% of Hemogenyx Pharmaceuticals shares are owned by institutional investors. 15.5% of Scancell shares are owned by company insiders. Comparatively, 10.0% of Hemogenyx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Hemogenyx Pharmaceuticals has a net margin of 0.00% compared to Scancell's net margin of -116.98%. Scancell's return on equity of 90.29% beat Hemogenyx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Scancell-116.98% 90.29% -45.28%
Hemogenyx Pharmaceuticals N/A -2,807.75%-37.79%

Hemogenyx Pharmaceuticals has lower revenue, but higher earnings than Scancell. Scancell is trading at a lower price-to-earnings ratio than Hemogenyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scancell£4.71M40.53-£6.75M-£0.55N/A
Hemogenyx PharmaceuticalsN/AN/A-£6.89K-£170.60N/A

Scancell has a beta of 0.71, indicating that its stock price is 29% less volatile than the broader market. Comparatively, Hemogenyx Pharmaceuticals has a beta of 1.496, indicating that its stock price is 50% more volatile than the broader market.

Summary

Scancell beats Hemogenyx Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

How does Hemogenyx Pharmaceuticals compare to BTG?

Hemogenyx Pharmaceuticals (LON:HEMO) and BTG (LON:BTG) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk, institutional ownership and media sentiment.

BTG's return on equity of 0.00% beat Hemogenyx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Hemogenyx PharmaceuticalsN/A -2,807.75% -37.79%
BTG N/A N/A N/A

BTG has a consensus target price of GBX 160, suggesting a potential upside of 36.54%. Given BTG's stronger consensus rating and higher probable upside, analysts plainly believe BTG is more favorable than Hemogenyx Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hemogenyx Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
BTG
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

0.2% of Hemogenyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 19.7% of BTG shares are owned by institutional investors. 10.0% of Hemogenyx Pharmaceuticals shares are owned by insiders. Comparatively, 19.7% of BTG shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, BTG had 7 more articles in the media than Hemogenyx Pharmaceuticals. MarketBeat recorded 7 mentions for BTG and 0 mentions for Hemogenyx Pharmaceuticals. BTG's average media sentiment score of 0.04 beat Hemogenyx Pharmaceuticals' score of 0.00 indicating that BTG is being referred to more favorably in the news media.

Company Overall Sentiment
Hemogenyx Pharmaceuticals Neutral
BTG Neutral

BTG has higher revenue and earnings than Hemogenyx Pharmaceuticals. Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than BTG, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hemogenyx PharmaceuticalsN/AN/A-£6.89K-£170.60N/A
BTG£159.40M1.18N/A£6.0019.53

Summary

BTG beats Hemogenyx Pharmaceuticals on 12 of the 12 factors compared between the two stocks.

How does Hemogenyx Pharmaceuticals compare to Arix Bioscience?

Hemogenyx Pharmaceuticals (LON:HEMO) and Arix Bioscience (LON:ARIX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, profitability, valuation, risk, institutional ownership and dividends.

Arix Bioscience has higher revenue and earnings than Hemogenyx Pharmaceuticals. Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Arix Bioscience, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hemogenyx PharmaceuticalsN/AN/A-£6.89K-£170.60N/A
Arix Bioscience£14.16M0.00£14.96M£0.11N/A

In the previous week, Hemogenyx Pharmaceuticals' average media sentiment score of 0.00 equaled Arix Bioscience'saverage media sentiment score.

Company Overall Sentiment
Hemogenyx Pharmaceuticals Neutral
Arix Bioscience Neutral

Hemogenyx Pharmaceuticals has a beta of 1.496, meaning that its stock price is 50% more volatile than the broader market. Comparatively, Arix Bioscience has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market.

0.2% of Hemogenyx Pharmaceuticals shares are held by institutional investors. Comparatively, 41.3% of Arix Bioscience shares are held by institutional investors. 10.0% of Hemogenyx Pharmaceuticals shares are held by insiders. Comparatively, 20.7% of Arix Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Arix Bioscience has a net margin of 105.64% compared to Hemogenyx Pharmaceuticals' net margin of 0.00%. Arix Bioscience's return on equity of 6.41% beat Hemogenyx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Hemogenyx PharmaceuticalsN/A -2,807.75% -37.79%
Arix Bioscience 105.64%6.41%2.18%

Summary

Arix Bioscience beats Hemogenyx Pharmaceuticals on 9 of the 10 factors compared between the two stocks.

How does Hemogenyx Pharmaceuticals compare to Circassia Group?

Hemogenyx Pharmaceuticals (LON:HEMO) and Circassia Group (LON:CIR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.

Circassia Group has higher revenue and earnings than Hemogenyx Pharmaceuticals. Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Circassia Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hemogenyx PharmaceuticalsN/AN/A-£6.89K-£170.60N/A
Circassia Group£27.90M0.00N/A£0.01N/A

Circassia Group's return on equity of 0.00% beat Hemogenyx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Hemogenyx PharmaceuticalsN/A -2,807.75% -37.79%
Circassia Group N/A N/A N/A

0.2% of Hemogenyx Pharmaceuticals shares are owned by institutional investors. 10.0% of Hemogenyx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Hemogenyx Pharmaceuticals' average media sentiment score of 0.00 equaled Circassia Group'saverage media sentiment score.

Company Overall Sentiment
Hemogenyx Pharmaceuticals Neutral
Circassia Group Neutral

Summary

Circassia Group beats Hemogenyx Pharmaceuticals on 5 of the 7 factors compared between the two stocks.

How does Hemogenyx Pharmaceuticals compare to Tiziana Life Sciences?

Hemogenyx Pharmaceuticals (LON:HEMO) and Tiziana Life Sciences (LON:TILS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.

Tiziana Life Sciences has lower revenue, but higher earnings than Hemogenyx Pharmaceuticals. Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Tiziana Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hemogenyx PharmaceuticalsN/AN/A-£6.89K-£170.60N/A
Tiziana Life Sciences-£3.60M0.00N/A-£16.30N/A

0.2% of Hemogenyx Pharmaceuticals shares are held by institutional investors. 10.0% of Hemogenyx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Tiziana Life Sciences' return on equity of 0.00% beat Hemogenyx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Hemogenyx PharmaceuticalsN/A -2,807.75% -37.79%
Tiziana Life Sciences N/A N/A N/A

In the previous week, Tiziana Life Sciences had 1 more articles in the media than Hemogenyx Pharmaceuticals. MarketBeat recorded 1 mentions for Tiziana Life Sciences and 0 mentions for Hemogenyx Pharmaceuticals. Hemogenyx Pharmaceuticals' average media sentiment score of 0.00 equaled Tiziana Life Sciences'average media sentiment score.

Company Overall Sentiment
Hemogenyx Pharmaceuticals Neutral
Tiziana Life Sciences Neutral

Summary

Tiziana Life Sciences beats Hemogenyx Pharmaceuticals on 5 of the 8 factors compared between the two stocks.

Get Hemogenyx Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for HEMO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HEMO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HEMO vs. The Competition

Export
MetricHemogenyx PharmaceuticalsBiotechnology IndustryMedical SectorLON Exchange
Market Cap£51.75M£496.86M£6.80B£2.77B
Dividend YieldN/A3.86%2.68%6.16%
P/E Ratio-4.463.1825.79366.66
Price / SalesN/A7,182.40550.5885,978.63
Price / Cash2.0513.1346.3327.87
Price / Book3,088.9988.5410.777.76
Net Income-£6.89K-£96.07M£3.57B£5.89B
7 Day Performance-7.08%1.95%3.15%-0.71%
1 Month Performance8.79%0.80%2.34%-1.20%
1 Year Performance390.97%72.01%33.42%65.93%

Hemogenyx Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HEMO
Hemogenyx Pharmaceuticals
N/AGBX 761
+3.0%		N/A+392.3%£51.75MN/AN/A14
SCLP
Scancell
N/AGBX 20.95
+1.0%		N/A+95.9%£217.42M£4.71MN/A51
BTG
BTG
4.5563 of 5 stars		GBX 119
-0.8%		GBX 160
+34.5%		N/A£191.72M£159.40M19.834,690
ARIX
Arix Bioscience
N/AN/AN/AN/A£183.73M£14.16M1,290.919
CIR
Circassia Group
N/AN/AN/AN/A£142.66M£27.90M3,400.00111

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:HEMO) was last updated on 6/26/2026 by MarketBeat.com Staff.
From Our Partners
Problems at SpaceX: time to get out?
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Solar is dead. Here’s what replaces it.
Starting July 4th, every new solar and wind project in America loses its federal tax credits. But one zero-car...
Behind the Markets | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Gold Will Hit $4,900
JPMorgan now sees gold hitting $4,900, and central banks are buying at a record 710 tonnes per quarter. Trump'...
Investors Alley | Sponsoredtc pixel
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...
Weiss Ratings | Sponsoredtc pixel
[Free Report] The 11-Hour Options Guide for Beginners - trade and ticker included
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel